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The role of antibody in protection of the vaginal mucosa and sensory ganglia against HSV-2 infection was examined using
HSV- immune, B-cell-deficient mMT mice. Significantly higher virus titers were detected in the vaginal mucosae of immune
mMT mice compared to immune C57BL/6J mice 24 h after HSV-2 rechallenge. However, virus was rapidly cleared in immune
mMT mice, and the infection was resolved with only a 2-day delay. Passive transfer of immune serum to immune mMT mice
prior to rechallenge resulted in HSV-specific vaginal IgG levels comparable to those of immune C57BL/6J mice. Although
transferred antibody failed to prevent reinfection of the majority of recipients, vaginal virus titers at 24 h and clearance
kinetics were similar to those of immune C57BL/6J controls. Following vaginal rechallenge, HSV-2 did not spread to the
sensory ganglia of immune C57BL/6J mice nor was the rechallenge virus detected in the ganglia of the majority of immune
mMT mice. However, protection was severely compromised by T-cell depletion of immune C57BL/6J mice. These results
suggest that HSV-specific antibody limits, but does not prevent, infection of the genital epithelia. Further, prevention of virus
spread to the sensory ganglia in immune animals requires vigorous T-cell immune responses. © 2000 Academic Press
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HSV-2 generally invades its host at the genital epithe-
lial surface, spreads to sensory neurons and achieves a
lifelong infection by establishing a latent infection in the
sensory ganglia (Stevens and Cook, 1971; Hill, 1985).
Periodic reactivation of latent HSV-2 results in production
of new virions that are released at the sensory nerve
ending. Although recurrent herpes disease may involve
the formation of lesions at the epithelial surface, recent
studies have demonstrated that subclinical recurrences
occur far more often than previously appreciated (Wald
et al., 1997). It has been suggested that this high fre-
quency of asymptomatic HSV-2 shedding may play an
important role in transmission of the virus (Mertz et al.,
1985; Rooney et al., 1986). HSV-2 infections can be life-
threatening to newborns and immunocompromised indi-
viduals (Whitley, 1996; Brown et al., 1987). Additionally,
the lesions can serve as an effective site of entry for
other sexually transmitted pathogens including the hu-
man immunodeficiency virus (Wasserheit, 1992; Holm-
berg et al., 1988). Therefore, the development of strate-
gies to prevent HSV transmission is a high priority.
A murine model of HSV-2 genital infection (McDermot
et al., 1984; Parr et al., 1994; Milligan and Bernstein, 1995)
has proven useful for examining the development of
genital immune responses and identifying specific im-
mune mechanisms that are important at the natural por-
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454tal of entry. HSV-specific antibody has been detected in
vaginal secretions of laboratory animals following inoc-
ulation with attenuated strains of HSV-2 (McDermot et al.,
1984; Parr et al., 1994; Milligan and Bernstein, 1995) or
recombinant viruses expressing HSV glycoproteins (Gal-
lichan and Rosenthal, 1996; Kuklin et al., 1998). Ideally,
his antibody might coat the mucosal surface and serve
s an immune barrier to prevent infection. The protection
rovided by maternal HSV-specific antibodies in prevent-
ng infection of newborns during vaginal delivery from
SV-infected mothers (Yeager et al., 1980; Ashley et al.,
992) and the ability of vaginally instilled HSV-specific
onoclonal antibodies to prevent infection of laboratory
nimals (Whaley et al., 1994) support the concept of an
immune barrier. In contrast, others have reported that
systemic administration of immune sera or HSV-specific
monoclonal antibodies to nonimmune mice does not
prevent infection following an HSV-2 intravaginal chal-
lenge (McDermot et al., 1990; Eis-Hubinger et al., 1993;
Parr and Parr, 1997). Additionally, Kuklin et al. (1998)
demonstrated that immunization with recombinant vac-
cinia viruses expressing HSV glycoproteins resulted in
high levels of HSV-specific IgG and IgA in vaginal secre-
tions but apparently did not prevent genital infection with
HSV-1.
There is also evidence suggesting that HSV-specific
antibody plays a role in preventing spread of virus to and
within the peripheral nervous system. Passive transfer of
HSV-specific antibodies to nonimmune recipients has
been shown to prevent or limit virus spread to sensory
ganglia (Price et al., 1975; Walz et al., 1976; McKendall et
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455ROLE OF ANTIBODY IN PROTECTION AGAINST HSV-2 INFECTIONal., 1979; Openshaw et al., 1979), although exceptions
ave been reported (Wildy, 1967; Cook and Stevens,
973). In a cutaneous model of zosteriform spread, a
ore extensive spread of virus within the sensory gan-
lia was demonstrated in B-cell-suppressed mice com-
ared to normal animals following HSV-1 inoculation
Simmons and Nash, 1987).
In previous studies, intravaginal inoculation with a
hymidine kinase deficient (tk2) strain of HSV-2 (HSV-2
k2) resulted in enhanced resistance to rechallenge with
fully virulent HSV-2 strain characterized by rapid clear-
nce of virus from the vaginal mucosa and the apparent
revention of HSV-2 spread to the sensory ganglia (Mil-
igan et al., 1998). In the current study, we utilized this
odel as a paradigm for efficient immunization against
enital HSV-2 infection. B-cell-deficient mMT mice were
mmunized by intravaginal inoculation with HSV-2 tk2
and then rechallenged with fully virulent HSV-2 to assess
the requirement for antibody-mediated protection in this
model. The results of this study suggest that levels of
vaginal HSV-specific antibody comparable to those at-
tained after natural infection substantially limited, but did
not prevent, infection of the genital epithelia. High titers
of HSV-specific antibody alone failed to prevent virus
reaching the sensory ganglia in the majority (78%) of
T-cell-depleted immune mice. By contrast, in the ab-
sence of specific antibody, rechallenge virus was not
detected in the sensory ganglia of the majority of im-
mune mMT mice. These results suggest that HSV vac-
cines designed to protect against the establishment of
HSV-2 latency in the sensory ganglia will need to induce
vigorous, long-lasting cell-mediated immune responses.
FIG. 1. Resolution of a primary vaginal HSV-2 tk2 infection in immu-
nocompetent and B-cell-deficient mice. Groups of 8 mMT and B6 mice
were inoculated intravaginally with 2.0 3 105 PFU HSV-2 tk2. Vaginalw
wabs were taken daily and titered on Vero cell monolayers. Results
hown are from a single representative experiment of three performed.RESULTS
Resolution of HSV-2 challenge of immune and
nonimmune mMT mice.
Given the sufficiency of cell-mediated immune re-
ponses to resolve epithelial HSV infections (Nash et al.,
987; Simmons and Nash, 1987), the requirement for and
otential protective role of specific antibody in the con-
ext of an immune animal is not completely understood.
o examine this issue, protection of the vaginal mucosa
as assessed in immune mice in the absence of specific
ntibody. B-cell-deficient mMT mice and B6 mice were
mmunized by intravaginal inoculation with HSV-2 tk2. As
hown in Fig. 1, virus was cleared from the vaginae of
mMT and B6 mice by Day 6 with nearly identical kinetics.
Four weeks after priming, immune B6 mice were control-
treated or depleted of T cells (90% depletion). These
mice, immune mMT mice, and age-matched nonimmune
B6 mice were then challenged intravaginally with fully
virulent HSV-2 strain 186. As shown in Fig. 2, relatively
low titers of HSV-2 were detected at 24 h in the vaginae
of control-treated immune B6 mice, and virus was com-
pletely cleared by Day 4. In comparison, virus titers at
24 h were 100-fold higher in immune mMT and T-cell-
depleted immune B6 mice. Interestingly, virus was
cleared rapidly in immune mMT mice, and these animals
xperienced only a 2-day delay in virus clearance com-
ared to control-treated immune B6 mice. However, virus
FIG. 2. Clearance of an HSV-2 challenge infection in immune mice
lacking antibody or T lymphocytes. Groups of 24 B6 and 12 mMT mice
ere immunized by intravaginal inoculation with HSV-2. Four weeks
ater 12 B6 mice were treated with monoclonal antibodies to deplete T
ells, and 12 were treated with an isotype-matched control monoclonal
ntibody. Immune mice and age-matched nonimmune B6 controls were
hallenged with 5 3 104 PFU HSV-2 strain 186. Results shown are from
a representative experiment of two performed.as not cleared from T-cell -depleted immune B6 mice,
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456 DUDLEY, BOURNE, AND MILLIGANand titers were comparable to nonimmune mice through
Day 5.
Comparison of HSV-specific T-cell immune response
in immune B6 and mMT mice
To determine whether the absence of B cells influ-
enced the nature of the HSV-specific T-cell response in
immune mMT mice compared to B6 mice, the cytokine
secretion profile of HSV-specific T cells from these mice
was determined by ELISPOT analysis prior to and 8 days
after intravaginal HSV-2 challenge. As shown in Fig. 3,
IL-4 secreting cells (SC) were detected in immune mice
prior to challenge. However, the majority of lymphocytes
from spleens and iliac lymph nodes (ILN) of HSV-immune
mice secreted interferon gamma (IFN-g) following anti-
gen stimulation. No significant differences were de-
tected in the proportion of HSV-specific, IFN-g SC to total
lymphocytes in the ILN or spleen of mMT mice compared
o B6 mice. However, cell counts were ;5.1-fold lower in
he spleen and 2.2-fold lower in the ILN of mMT mice
ompared to B6 mice, indicating that fewer total HSV-
pecific T cells were present in mMT compared to B6
ice prior to challenge. HSV-2 challenge of immune
mMT and B6 mice resulted in expansion of the HSV-
specific population in both spleen and ILN and the re-
sponse was again predominantly Th1-like as measured
on Day 8 after challenge. No significant difference was
detected in the proportion of HSV-specific, IFN-g secret-
ing lymphocytes in the ILN of immune mMT mice com-
pared to immune B6 mice. However, the proportion of
HSV-specific, IFN-g SC to total lymphocytes was signif-
cantly lower in the spleens of immune mMT mice com-
ared to immune B6 mice (P , 0.01). Again, cell counts
ere ;4.4-fold lower in spleens and 2.6-fold lower in ILN
f mMT compared to B6 mice, indicating the presence of
fewer antigen-specific T cells in the lymphoid tissue of
immune mMT mice. Previous studies have demonstrated
-cell-dependent production of IFN-g in vaginal secre-
ions of HSV-immune mice within 24 h after HSV-2 chal-
enge (Milligan et al., 1998; Parr and Parr, 1999). Vaginal
FN-g levels in immune mMT mice were comparable to
those of immune B6 mice on Days 1–4 after challenge,
suggesting that the T cell response at the site of infection
was comparable between strains (G. Milligan, unpub-
lished results).
The quality of the immune response was also as-
sessed by quantification of specific cytokines in culture
supernatants of HSV antigen-stimulated lymphocytes. As
shown in Fig. 4, production of IFN-g was antigen-spe-
cific, and high levels of IFN-g were produced by HSV-
timulated spleen and ILN cells from both immune mMT
nd B6 mice. No significant difference was detected in
he amount of IFN-g produced by B6 compared to mMT
ILN cells. However, significantly less IFN-g was pro-
duced in mMT spleen cell cultures compared to B6spleen cultures (P , 0.001), most likely reflecting the
lower proportion of IFN-g producing cells in this tissue in
mMT mice (Fig. 3). Significantly less IL-2 was detected in
both ILN (P , 0.005) and spleen cell (P , 0.001) cultures
from immune mMT mice. IL-4 was detected, at low levels,
only in spleen cell cultures from immune mMT mice (G.
FIG. 3. HSV-specific cytokine SC from spleens and ILN of immune B6
and mMT mice. Groups of 10–12 mice were immunized intravaginally
with HSV-2 tk2. Lymphocytes were harvested 4 weeks later prior to
SV-2 challenge (open bars) or 8 days after HSV-2 challenge (closed
ars), and cells from 3–4 mice were pooled (2–3 pools/group in each
xperiment) and stimulated with nonviable HSV-2 antigen. Data are
resented as the mean number of cytokine SC/106 mononuclear cells
(MNC). Each value represents the mean results 6 SE from three to five
xperiments. Results from Vaccinia virus (V V) antigen-stimulated cul-
ures are omitted for figure clarity. The mean number of IL-4 SC/106
MNC detected following VV stimulation was 10 for all prechallenge
cultures and ranged from 0 (naive spleen cells) to 116 (immune B6 ILN
cells) for Day 18 cultures. The mean number of IFNg-secreting cells/
106 MNC detected following VV stimulation was ,32 in all prechal-
enge cultures and ranged from 2 (Naive ILN cells) to 54 (immune B6
LN cells) for Day 18 cultures.Milligan, unpublished results).
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457ROLE OF ANTIBODY IN PROTECTION AGAINST HSV-2 INFECTIONRole of HSV-specific antibody in protection of the
vaginal mucosae of HSV-immune mice
To determine whether the early deficit in protection
against challenge infection observed in immune mMT
mice could be compensated for by antibody, HSV-im-
mune or normal serum was passively transferred to
immune mMT mice prior to HSV-2 challenge. This al-
lowed a comparison of the effect the presence of specific
antibody had on initial virus titers in immune mice ex-
pressing equivalent levels of T-cell immunity. For further
comparison, immune B6 mice were depleted of T cells
(;95% depletion) or control-treated prior to HSV-2 chal-
lenge. As expected, HSV-specific IgG was not detected
in vaginal secretions of mMT mice that received normal
erum prior to HSV-2 challenge (Table 1). By contrast,
SV-specific IgG was detected in vaginal secretions of
FIG. 4. Quantification of cytokines in culture supernatants from
antigen-stimulated lymphocytes from immune mMT and B6 mice. Lym-
phocytes were harvested from spleens and ILN of naive B6, immune
mMT, and immune B6 mice and cells from three to four mice were
pooled (2–3 pools/group in each experiment). Equal numbers of cells
(4 3 106) from each group were stimulated with HSV or VV Ag. IL-2 was
quantified in 24 h supernatants and IFN-g was quantified in 48 h
supernatants by capture ELISA. Results shown represent the mean 6
SE of three experiments.SV immune serum recipients prior to challenge at lev-
t
ils comparable to those of immune B6 mice. Antibody
evels were maintained in vaginal secretions of mMT
mmune serum recipients while levels increased in im-
une B6 mice through Day 8 after challenge.
High titers of HSV-2 were detected at 24 h post chal-
enge, and virus was not cleared from the vaginae of
onimmune B6 mice (Fig. 5). However, a decrease in
irus titer of ;100-fold was observed at 24 h after chal-
enge in immune B6 compared to nonimmune B6 mice,
TABLE I
Quantification of HSV-Specific Antibody in Vaginal Secretions
Following Passive Transfer of HSV-Immune Serum
Mice Treatmenta
HSV-specific IgG (ng/ml)
Day 21b Day 18
Nonimmune B6 None ,0.05 NDc
Immune mMT Normal sera ,0.05 ,0.05
mmune mMT Immune sera 7.5 6 3.8 6.5 6 1.9
mmune B6 T cell depleted 2.9 6 0.9 43.6 6 21.1
mmune B6 Control IgG 5.1 6 1.4 41.7 6 21.3
a Immune mMT mice received 0.3 ml normal sera or HSV-immune
erum intraperitoneal. One group of immune B6 mice were depleted of
cells prior to challenge.
b Vaginal secretions were collected by lavage on Day 21 and Day
18 relative to challenge.
c ND, not determined. No nonimmune B6 mice survived by Day 18.
FIG. 5. Effect of passively transferred HSV-specific antibody on clear-
ance of HSV-2 from the vaginal mucosae of immune mMT mice. Groups
f 16 B6 and mMT mice were immunized with HSV-2 tk2. Four weeks
later, groups of 8 immune mMT mice received 0.3 ml HSV-immune- or
ormal mouse sera intraperitoneally 3 days before HSV-2 challenge.
roups of eight immune B6 mice were depleted of T cells or control-reated prior to challenge. Results shown are from an individual exper-
ment of two performed.
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458 DUDLEY, BOURNE, AND MILLIGANand virus was cleared from the vagina by Day 3. As
demonstrated previously (Fig. 2), depletion of T cells from
immune B6 mice resulted in HSV-2 titers comparable to
those of nonimmune mice and a failure to clear virus.
Virus titers in immune mMT mice receiving normal serum
ere ;50-fold higher on Day 1 compared to immune B6
ice, and clearance of HSV-2 was delayed by ;3 days.
n two separate experiments, administration of immune
erum to immune mMT mice prior to challenge failed to
prevent infection in the majority of mice. Twelve of 16
immune mMT mice receiving immune serum were in-
fected after rechallenge compared to 16/16 immune B6
and 16/16 immune mMT mice receiving normal serum.
Although slightly lower, the incidence of infection of im-
mune mMT immune serum recipients was not signifi-
antly different from naive serum recipients or immune
6 mice. Virus titers in immune serum recipients at 24 h
ere comparable to those of immune B6 mice, and virus
as cleared with similar kinetics. Similar results were
btained when mice were challenged with a 10-fold
ower virus inoculum (G. Milligan, unpublished results).
ole of antibody in protection of the sensory ganglia
f HSV-immune mice
Inoculation of laboratory animals with attenuated
trains of HSV-2 has been shown to protect the sensory
anglia against acute infection by fully virulent HSV-2
trains (Stanberry et al., 1986; Milligan et al., 1998). To
examine the requirement for HSV-specific antibody in
protection of the sensory ganglia in immune mice, im-
mune mMT mice were injected with HSV-immune or
ormal serum, and the ability of these animals to resist
T
Protection of Sensory Ganglia and Central Nervous Sys
Mice Tissue
Day 6
Percentage of
virus-positive
samplesa
Mean titer PF
(log 10) in
samp
Nonimmune B6 Ganglia 100 (8/8) 3.84 6
Spinal cord 100 (8/8) 4.03 6
mmune B6, Ganglia 0 (0/8) ,c
control IgG Spinal cord 0 (0/8) ,
mmune B6, Ganglia 75 (6/8) 3.01 6
T-cell depleted Spinal cord 75 (6/8) 3.43 6
mmune mMT, Ganglia 0 (0/8) ,
immune sera Spinal cord 0 (0/8) ,
mmune mMT, Ganglia 0 (0/10) ,
normal sera Spinal cord 30 (3/10) 2.44 6
a Only tissues from mice with positive vaginal swabs on Day 1 were
ice with negative vaginal swabs.
b ND, not determined. Nonimmune B6 mice did not survive to Day 1
c HSV-2 titers indicated by “,” fell below the level of detection of 50cute HSV-2 infection of the sensory ganglia was as-essed. As shown in Table 2, infectious HSV-2 was
resent at high titers in the sensory ganglia of nonim-
une B6 mice on Day 6 after challenge. Infectious HSV-2
as not detected in the sensory ganglia of any HSV-
mmune B6 mouse following intravaginal challenge.
owever, virus was detected in the sensory ganglia from
he majority (78%) of T-cell-depleted, HSV-immune mice.
n contrast, virus was detected in the ganglia of only 4%
f B-cell-deficient immune mMT mice that received nor-
mal serum and was not detected in any immune mMT,
mmune serum recipient. Additionally, there was no sig-
ificant difference in the incidence of infected spinal
ords between immune mMT mice receiving normal or
immune sera. Similar results were obtained in experi-
ments in which mice were challenged with a 10-fold
lower virus inoculum (G. Milligan, unpublished results).
DISCUSSION
Since many viruses infect their host at mucosal sur-
faces there is considerable interest in developing immu-
nization methods to elicit a mucosal antibody “barrier”
capable of preventing infection. Secretory IgA (S-IgA)
antibody is preferentially found in large quantities at
mucosal sites, and it has often been assumed that for-
mation of such a “barrier” will require induction of S-IgA
responses. While S-IgA is the predominant antibody iso-
type found in vaginal secretions of mice, the majority of
HSV-specific antibody detected in vaginal secretions of
HSV-immune mice is IgG (Milligan and Bernstein 1995a;
Parr et al., 1998). Other studies have demonstrated ef-
fective neutralization of HSV-2 by vaginal IgG (Parr and
Parr, 1997). However, recent reports of an HSV-glycopro-
Immune mMT Mice Receiving Immune or Normal Sera
Day 8 Total
SE Percentage of
virus-positive
samples
Mean titer PFU/g 6 SE
(log 10) in positive
samples
Positive
samples
(Days 6 and 8)
NDb ND 100 (8/8)
ND ND 100 (8/8)
0 (0/11) , 0 (0/19)
0 (0/11) , 0 (0/19)
80 (8/10) 3.68 6 0.75 77.8 (14/18)
90 (9/10) 3.67 6 0.73 83.3 (15/18)
0 (0/11) , 0 (0/19)
0 (0/11) , 0 (0/19)
8.3 (1/12) 3.60 4.5 (1/22)
8.3 (1/12) 4.26 18.2 (4/22)
d in this analysis. No virus was detected in ganglia or spinal cords of
is set of experiments.
l.ABLE 2
tem in
U/g 6
positive
les
0.71
0.72
0.44
0.60
0.31
includetein vaccine that induced high titers of neutralizing anti-
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459ROLE OF ANTIBODY IN PROTECTION AGAINST HSV-2 INFECTIONbody but failed to prevent genital HSV-2 infection in
clinical trial highlight questions about the efficacy of
antibody-mediated protection against HSV-2 in the gen-
ital tract (Corey et al., 1999). The results of the current
study suggest that HSV-specific antibody, at levels
achieved following a “natural” infection, does not prevent
HSV-2 reinfection but can aid in protection of the vaginal
mucosa. Additionally, an HSV-specific antibody re-
sponse, in the absence of a cell- mediated response,
was ineffective at preventing an acute infection of the
sensory ganglia of immune mice. In contrast, in the
absence of specific antibody, the cell-mediated re-
sponses of immune mice were more effective in prevent-
ing acute infection of the sensory ganglia.
The T-cell-dependent nature of the resolution of a
primary vaginal HSV-2 infection has been demonstrated
previously (Milligan and Bernstein 1995b) and clearance
of HSV-2 tk2 from the vagina is normally accomplished
before HSV-specific antibody can be detected in either
serum or vaginal secretions (Milligan and Bernstein,
1995a). The ability of B-cell-deficient mMT mice to re-
olve a primary vaginal infection with HSV-2 tk2 (Fig. 1)
as consistent with these previous results. Additionally,
ntibody-deficient immune mice were fully capable of
esolving a challenge infection with fully virulent HSV-2
Fig. 2), and the presence of high titers of HSV-specific
gG in vaginal secretions failed to protect T-cell-depleted
SV-immune B6 mice against intravaginal challenge
ith fully virulent HSV-2 (Figs. 2 and 5). Although these
esults suggest that antibody was neither required nor
ufficient for protection, results of the current study sug-
est that HSV-specific antibody played an early benefi-
ial role in the vaginal mucosa of immunized animals.
irus titers were 10- to 100-fold higher at 24 h after
nfection in immune mMT mice compared to immune B6
controls. Passive transfer of HSV-specific sera to im-
mune mMT mice did not prevent infection of the vaginal
pithelium; however, it apparently limited the extent of
nfection as reflected by the greater than 100-fold reduc-
ion in 24-h virus titers compared to immune mMT normal
erum recipients. Therefore although the cell-mediated
echanisms operating in immune mMT mice were suf-
icient to clear HSV-2, the addition of HSV-specific anti-
ody to these mice reduced initial virus titers and re-
ulted in the resolution of the challenge infection 2–3
ays earlier than in immune mMT mice that received
normal serum.
These results differ somewhat from those of Daheshia
et al. (1999) in which initial virus titers and clearance
kinetics in HSV-immune mMT and immune control mice
ere similar following ocular challenge with HSV-1. It is
ossible the method of inoculation may impact the pro-
ective capacity of specific antibody. The mechanical
amage done by scarification of the cornea prior to
noculation promotes viral invasion, possibly by provid-
ng a more direct route of infection to susceptible cells nnd nerve termini. Rapid infection of corneal cells under
hese conditions may limit protection afforded by anti-
ody-mediated neutralization of extracellular virus. By
ontrast, mice were directly inoculated onto a relatively
ndisrupted mucosal surface in the current study. It is
ossible that virus infection of an intact epithelial layer is
ess efficient and allows for a longer exposure of virus to
pecific antibody. Alternatively, the vaginal environment
ncluding mucous and resident phagocytic cells may be
ore capable of antibody-mediated trapping and re-
oval of infectious virions than is the corneal micro-
nvironment.
The results of the current studies demonstrate that an
ffective T-cell response developed in mMT mice in the
bsence of B cells, and that this response was similar,
ut not identical, to that of immune B6 controls. The
ajority of HSV-specific T cells in immune mMT and B6
mice were Th1-like. Further, HSV-specific, IFN-g-secret-
ing T cells comprised a similar proportion of the total
lymphocytes from regional lymph nodes from both
strains of mice (Fig. 3). However, as noted previously by
Topham et al. (1996), the secondary lymphoid tissue of
mMT mice was less cellular than that of B6 controls
resulting in fewer total antigen-specific lymphocytes in
mMT animals. Although the frequencies and immune
functions of antigen-specific mMT T cells have been
eported to be similar to those of B6 controls in other
irus systems (Philips et al., 1996; Asano and Ahmed,
996; Mozdzanowska et al., 1997; Topham and Doherty,
998), negative effects of B-cell depletion on developing
ntiviral T-cell responses (Schultz et al., 1990) and defi-
iencies in helper function and IFN-g and IL-2 production
by mMT CD41 T cells have also been reported (Homann
et al., 1998). In the present study, the cytokine secretion
profile and proportion of IFN-g-secreting T cells to total
lymphocytes in the regional lymph nodes was similar
between strains. Similar quantities of IFN-g were de-
tected in cultured lymph node cells although, in agree-
ment with the study of Homann et al. (1998), significantly
less IL-2 was detected in culture supernatants of lym-
phocytes from the regional lymph nodes of immune mMT
mice. The effect this difference in IL-2 secretion may
have had on the response to HSV-2 challenge is unclear
as the number of HSV-specific T cells in both immune
mMT and immune B6 mice apparently increased through
Day 8 after challenge (Fig. 3). It is possible that sufficient
IL-2 was present locally to drive T-cell expansion or that
other cytokines, such as IL-15, that share similar activi-
ties with IL-2 compensated for the lower IL-2 production
by immune mMT T cells.
The T-cell-dependent nature of HSV-2 clearance dur-
ng primary and rechallenge infections has been dem-
nstrated previously (Milligan and Bernstein, 1997; Mil-
igan et al., 1998). Further, it has been demonstrated that
T-cell function manifested within 24 h of challenge wasecessary for protection of immune mice against vaginal
cf
p
t
s
p
a
t
T
(
460 DUDLEY, BOURNE, AND MILLIGANHSV-2 challenge (Milligan et al., 1998; Parr and Parr
1998). Thus it was not possible to demonstrate a protec-
tive effect of HSV-specific antibody alone in the absence
of T-cell immunity (Figs. 2 and 5). It is therefore possible
that the difference in initial virus titers between immune
mMT and immune B6 mice reflected a deficiency in the
T-cell response of immune mMT mice rather than a lack
of initial protection by antibody. Three lines of evidence
from the current study suggest that mMT T-cell re-
sponses were not functionally deficient in protection
against HSV-2. First, resolution of a primary HSV-2 tk2
vaginal infection in non-immune mMT and B6 mice oc-
urred with identical kinetics (Fig. 1). Second, immune
mMT mice resolved a challenge infection within 2 days of
immune B6 mice despite initial virus titers that were
100-fold higher in these mice (Fig. 2). Third, IFN-g was
detected at comparable concentrations in vaginal secre-
tions of both immune mMT and B6 mice after challenge,
suggesting that genital T-cell responses were compara-
ble between strains (G. Milligan unpublished results).
Additionally, Daheshia et al. (1999) demonstrated that
immune mMT and control mice cleared HSV-1 from the
eye with identical kinetics despite decreased cell num-
bers in secondary lymphoid tissues of mMT mice. There-
ore although these results do not completely rule out the
ossibility of functionally deficient mMT T-cell responses,
he reduction in virus titer in immune mMT mice receiving
HSV-immune compared to normal serum clearly demon-
strates an early beneficial effect of specific antibody. The
present study did not directly identify the antibody iso-
type responsible for the initial protective effect. Because
the HSV-specific antibody found in serum of HSV-inocu-
lated mice is predominantly IgG (Milligan and Bernstein,
1995a), transfer of immune serum would have resulted in
higher levels of HSV-specific IgG relative to IgA. Other
studies have demonstrated superior neutralization of
HSV-2 by antigen-specific IgG compared to IgA antibody
(Parr and Parr, 1997). Together, these findings suggest
that the protective effect of transferred serum was most
likely provided by IgG antibody.
The amount of antibody at a given mucosal surface
and the length of time the virus inoculum is exposed to
antibody may influence the effectiveness of antibody-
mediated protection. Further, the importance of antibody-
mediated protection of mucosal surfaces against viral
pathogens is most likely dependent on the specific virus
involved and its natural history of infection. The current
results and those of Daheshia et al. (1999) suggest that
protection of mucosal surfaces against HSV does not
require antibody. However, Franco and Greenberg (1995)
found that B cells were absolutely necessary for protec-
tion against rotavirus infection of the gastrointestinal
tract. Additionally, Mascola et al. (2000) presented results
suggesting that neutralizing IgG antibodies could confer
protection against vaginal transmission of a simian-hu-
man immunodeficiency virus chimera in rhesus ma-caques. The protective role of cell-mediated responses
against HSV may be similar to that observed in a murine
reovirus system (Virgin and Tyler, 1991) in which adop-
tively transferred immune T cells controlled primary rep-
lication of virus in the gut mucosa of neonatal recipient
mice. Interestingly, a passively transferred monoclonal
antibody was more effective than immune cells at pre-
venting neural spread of the virus.
Numerous studies have demonstrated the protective
effect of passively transferred HSV-specific antibodies
against spread of HSV to the peripheral and central
nervous systems (Wildy, 1967; Cook and Stevens, 1973;
Price et al., 1975; Walz et al., 1976; McKendall et al., 1979;
Openshaw et al., 1979), although results vary according
to the site of inoculation and virus strain employed.
Using a model of zosteriform HSV-1 spread, Simmons
and Nash (1987) demonstrated that spread of virus to
and within the peripheral nervous system following pri-
mary cutaneous inoculation was more extensive in B-
cell-suppressed mice. Zosteriform lesions, indicative of
virus spread within the sensory ganglia, were detected in
B-cell-suppressed immune animals only after rechal-
lenge with very high HSV-1 doses, suggesting an impor-
tant role for cell mediated immune responses in protec-
tion of the sensory ganglia. Because HSV-2 is more
neurovirulent than HSV-1 (Plummer et al., 1970; Walz et
al., 1977; Richards et al., 1981), we hypothesized that
immune protection of the sensory ganglia against HSV-2
infection might require a combination of mechanisms or
more vigorous immune responses. However, cell-medi-
ated immunity alone was sufficient to prevent acute rep-
lication of HSV-2 in the sensory ganglia of most, but not
all, immune mMT mice (Table 2). By contrast, HSV-2
pread rapidly to the lumbosacral ganglia of T-cell-de-
leted immune B6 mice, suggesting that HSV-specific
ntibody alone, at levels attained following natural infec-
ion, did not prevent spread to the sensory ganglia.
hese results support those of Morrison and Knipe
1997) demonstrating a role for CD41 lymphocytes in
immune protection of the ganglia. Rather than preclude a
role for antibody, these results highlight the importance
of strong cell-mediated responses in immune protection
of the sensory ganglia. These results are also in agree-
ment with studies in other HSV models that demon-
strated a protective effect of passively transferred anti-
body only in the presence of at least one T cell subset
(Oakes et al., 1980; Minagawa et al., 1990; Eis-Hubinger
et al., 1993; Staats et al., 1991). The nature of this T-cell
involvement in protection of the sensory ganglia is not
well understood. However, it seems likely that T-cell
responses restrict virus replication within the mucosa
and limit the amount of virus reaching the nerve endings.
In the absence of these responses, the antibody-medi-
ated protection of the sensory nerve endings may be
overwhelmed, allowing virus to reach the sensory gan-
glia.
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461ROLE OF ANTIBODY IN PROTECTION AGAINST HSV-2 INFECTIONBecause vaccination is not likely to completely prevent
infection of the genital epithelia by HSV-2 (Corey et al.,
1999), successful vaccines will most likely need to elicit
immune responses that can prevent or restrict spread of
virus to the sensory ganglia. Although numerous studies
have demonstrated the ability of antibody to limit spread
of HSV to the sensory ganglia, the results of the current
study suggest that vigorous T-cell responses are also
required for optimum protection. Because of the local
nature of protective T-cell responses (Cunningham et al.,
1985; Koelle et al., 1998), it will be important to ensure
that HSV vaccines elicit appropriate local T-cell re-
sponses or, alternatively, elicit T cells capable of homing
rapidly to the genital mucosa or sensory ganglia after
HSV-2 exposure.
MATERIALS AND METHODS
Virus
The thymidine-kinase-deficient HSV-2 strain 333
(HSV-2 tk2) and fully virulent HSV-2 strain 186 were
obtained originally from Dr. Lawrence Stanberry (Chil-
dren’s Hospital Medical Center, Cincinnati, OH).
Mice
B-cell-deficient mMT mice (Kitamura et al., 1991) on a
C57BL/6 genetic background were obtained by permis-
sion of Dr. Werner Muller (Institute for Genetics, Univer-
sity of Cologne, Cologne, Germany) from the Jackson
Laboratory (Bar Harbor, ME) and were bred at the Chil-
dren’s Hospital Research Foundation animal facility. Age-
matched control C57BL/6J (B6) mice were obtained from
the Jackson Laboratory. All mice were housed in specific
pathogen-free conditions in sterile micro-isolator cages.
Intravaginal inoculation of mice
Mice received two subcutaneous injections of 3 mg
medoxyprogesterone acetate (Upjohn Company, Kalama-
zoo, MI) in a 1-week period. Anesthetized mice were
swabbed with a calcium alginate swab and inoculated
by instillation of 20 ml HSV-2 into the vaginal lumen. Mice
were immunized by inoculation with 2 3 105 plaque
orming units (PFU) HSV-2 tk2 and challenged intravag-
nally with doses of HSV-2 strain 186 from 5 3 104–5 3
05 PFU. Nonimmune mice pretreated with progesterone
are susceptible to vaginal HSV-2 infection as defined by
the presence of virus in the vagina for several days after
inoculation (Parr and Parr, 1997; Milligan et al., 1998). In
contrast, no virus was detected at 24 h in mice inocu-
lated during the estrous phase of the reproductive cycle,
indicating that the infection does not take and the origi-
nal inoculum does not remain viable in the mouse vagina
(G. Milligan, unpublished results). Therefore virus de-
tected at 24 h represents replicating virus and not the
original inoculum. mQuantification of HSV-specific antibody
Vaginal secretions were obtained as described previ-
ously and diluted to 225 ml (Milligan and Bernstein,
995a; Milligan et al., 1998). Two rows of 96-well assay
lates were coated with anti-mouse immunoglobulin
Caltag, San Francisco, CA). The remaining wells were
oated with HSV-2 glycoprotein or a control glycoprotein
reparation from uninfected Hep-2 cells. A standard
urve was prepared on each plate by plating a series of
wofold dilutions of purified mouse IgG (Sigma-Aldrich
hemical Company, St. Louis, MO) in the anti-mouse
mmunoglobulin-coated wells. A series of threefold dilu-
ions of vaginal lavage samples were plated in duplicate
n HSV- and control glycoprotein-coated wells. The
lates were incubated at ambient temperature for 1 h,
ashed, and then developed by sequential addition of
iotinylated anti-mouse IgG antibody (Southern Biotech-
ology, Birmingham, AL), HRP-conjugated goat anti-bi-
tin antibody (Vector Laboratories, Birlingame, CA) and
-phenylenediamine dihydrochloride (OPD) plus hydro-
en peroxide (Sigma-Aldrich). The OD490 was determined
on a Thermo Max microplate reader (Molecular Devices,
Sunnnyvale, CA). The OD490 of experimental samples
were compared to standard values over the linear por-
tion of the standard curve, and antibody concentrations
were calculated using the Softmax software program
(Molecular Devices). Because an unknown dilution of
vaginal secretions was performed during lavage, the
results are expressed as ng HSV-specific IgG/ml in the
225-ml sample.
n vivo depletion of T cells
Semipurified stocks of monoclonal antibody were pre-
ared as described previously (Milligan and Bernstein,
997; Milligan et al., 1998). Mice were injected intraperi-
oneally on alternating days beginning 6 days before
SV-2 challenge with 2 mg anti-Thy 1.2 (30-H12) or a
ixture of anti-CD4 (GK1.5) and anti-CD8 antibody (2.43)
1 mg each). Control mice were treated with an isotype-
ontrol monoclonal antibody (SFR8.B6, specific for HLA-
w6). Treatment was continued through Day 6 after chal-
enge and resulted in depletion of 90–95% of T cells from
LN as determined by flow cytometry (G. Milligan, unpub-
ished results).
uantification of IFN-g and IL-4 SC by ELISPOT
analysis
Spleen or ILN lymphocytes from three to five animals
were pooled and cultured in 24-well plates with either
nonviable HSV or vaccinia virus (VV) antigen. After 48 h,
serial 10-fold dilutions of cultured cells were plated on
nitrocellulose plates that had been coated previously
with purified R4–6A2 (anti-IFN-g) or 11B11(anti-IL-4)onoclonal antibody. Feeder cells from normal B6 mice
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462 DUDLEY, BOURNE, AND MILLIGANwere added, and cultures were incubated an additional
18 h in the presence of antigen. Plates were washed
extensively followed by sequential addition of biotinyl-
ated anti-IFN-g or biotinylated anti-IL-4 (Pharmingen, San
Diego, CA), avidin-peroxidase (Sigma-Aldrich), and
3-amino-9 ethyl-carbazole plus hydrogen peroxide sub-
strate. Spots were counted with the aid of a dissecting
microscope. Wells containing only feeder cells routinely
had 0–2 spots/well, and this number was subtracted
from the spot totals of wells containing antigen-stimu-
lated immune lymphocytes plus feeder cells.
Detection of HSV-2 in the vagina, sensory ganglia,
and spinal cord
The vaginae of mice were swabbed daily with moist
calcium alginate swabs. Swabs were stored in 1 ml
titration media (Media 199 plus 2% newborn calf serum,
2% penicillin/streptomycin, 2% amphotericin B) at 270°C
until titration on Vero cell monolayers. Sensory (lumbo-
sacral) ganglia and spinal cords were dissected,
weighed, and homogenized in 1 ml cold titration media.
Cell debris were removed by centrifugation at 5°C, and
serial dilutions of homogenates were plated on Vero cell
monolayers.
Passive transfer of immune or nonimmune sera
Immune serum was prepared by intravaginal inocula-
tion of mice with 5 3 105 PFU HSV-2 tk2. Four weeks
later, mice were challenged intravaginally with 106 PFU
HSV-2 strain 186. Sera were collected weekly from im-
mune mice or age-matched nonimmune mice beginning
2 weeks after challenge, then pooled and stored frozen
at 220°C until use. Mice received a single intraperito-
neal injection of 0.3 ml immune or normal sera 3 days
before challenge with HSV-2 strain 186.
Statistical analysis
Data were analyzed by one-way ANOVA with the Bon-
ferroni correction for multiple groups or Student’s t test
as appropriate. Incidence of infection was compared
between groups using Fisher’s exact test (2-tailed).
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